13F Holdings
中文EN

PBH Prestige Consumer Healthcare Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1295947 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.1%
TTM net income YoY-22.8%
TTM EPS YoY-19.8%
Revenue 3-yr CAGR1.2%
Net income 3-yr CAGR—

Margins

Gross margin52.5%
Operating margin25.0%
Net margin13.3%
FCF margin18.4%
EBITDA margin28.1%

Returns

ROE8.2%
ROA3.8%
ROIC (approx.)6.9%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets58.8%
Debt / equity1.07x
Current ratio2.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.48x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue$1.09B$1.14B$1.13B$1.13B$1.09B
Cost of revenue$493.13M$503.30M$500.91M$502.43M$466.17M
Gross profit$595.58M$634.46M$624.45M$625.29M$620.65M
SG&A expense$116.45M$108.21M$106.15M$107.35M$107.46M
Operating income$309.41M$336.77M$342.43M-$22.41M$329.92M
Interest expense—$1.80M$5.20M$4.40M$64.29M
Pretax income$257.50M$284.19M$276.02M-$93.92M$262.46M
Income tax$67.19M$69.58M$66.69M-$11.61M$57.08M
Net income$190.30M$214.60M$209.34M-$82.31M$205.38M
EBITDA$340.68M$366.95M$373.10M$10.21M$362.01M
EPS (basic)3.934.324.21-1.654.09
EPS (diluted)3.914.294.17-1.654.04
Weighted avg. shares (diluted)48.72M50.08M50.18M49.89M50.84M
Banking
Net interest income-$42.34M-$47.63M-$67.16M-$69.16M-$64.29M
Provision for credit losses$10.33M$0$0——
Balance sheet
Cash & equivalents$63.87M$97.88M$46.47M$58.49M$27.18M
Receivables$191.92M$194.29M$176.78M$167.02M$139.33M
Inventory$159.13M$147.71M$138.72M$162.12M$120.34M
Current assets$431.48M$448.33M$375.04M$391.74M$293.27M
PP&E, net$121.69M$74.55M$76.51M$70.41M$71.30M
Goodwill$581.11M$527.42M$527.73M$527.55M$578.98M
Intangibles$2.30B$2.30B$2.32B$2.34B$2.70B
Total assets$3.49B$3.40B$3.32B$3.35B$3.67B
Current liabilities$120.92M$106.62M$117.05M$160.72M$143.42M
Short-term debt$0————
Long-term debt$993.95M$992.36M$1.13B$1.35B$1.48B
Total debt$993.95M$992.36M$1.13B$1.35B$1.48B
Total liabilities$1.61B$1.57B$1.66B$1.91B$2.09B
Shareholders' equity$1.89B$1.83B$1.66B$1.45B$1.58B
Net debt$930.09M$894.47M$1.08B$1.29B$1.45B
Cash flow statement
Operating cash flow$257.63M$251.51M$248.93M$229.72M$259.92M
Capital expenditure$11.18M$8.22M$9.55M$7.78M$9.64M
Free cash flow$246.45M$243.29M$239.38M$221.93M$250.28M
Investing cash flow-$136.84M-$17.45M-$20.11M-$11.58M-$256.51M
Financing cash flow-$156.06M-$182.07M-$241.01M-$185.85M-$7.57M
Depreciation & amortization$31.27M$30.17M$30.68M$32.62M$32.09M
Stock-based compensation$10.84M$11.16M$14.01M$12.40M$9.04M
Share buybacks$156.28M$51.51M$25.00M$50.00M$0

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.